DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for familial hypocalciuric hypercalcemia 3 — screening already-approved drugs against its 1-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleFamilial hypocalciuric hypercalcemia 3 maps to a 1-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for familial hypocalciuric hypercalcemia 3 is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
adaptor related protein complex 2 subunit sigma 1 (AP2S1) — AP2S1 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet apo structuredrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 6URI · 3.0 Å · ligand none (apo structure). Experimental structure, not a prediction.
What the evidence adds up to
Familial hypocalciuric hypercalcemia type 3 (FHH3) is a genetic disorder of calcium homeostasis caused by a mutation in the AP2S1 gene. A 2021 case report describes a 36-year-old man who was initially misdiagnosed with primary hyperparathyroidism and underwent a parathyroidectomy at another institution, only to develop recurrent symptomatic hypercalcemia. Genetic testing later revealed a c.43C>T (p.Arg15Cys) mutation in AP2S1, confirming FHH3. His father and sister also had hypercalcemia and were offered genetic testing. The report notes that some FHH3 patients have symptomatic hypercalcemia and associated cognitive issues.
FHH in general is described in older abstracts as a rare, benign, and usually asymptomatic condition inherited in an autosomal dominant pattern. A 2013 case report describes a young diabetic man hospitalised for necrotising fasciitis who had persistent hypercalcemia during recovery. A 1997 review states that most FHH cases are caused by inactivating missense mutations in the calcium-sensing receptor (CASR), but at least two other FHH genes exist and had not yet been identified at that time. A 2018 overview notes that FHH usually requires no treatment, whereas the related neonatal severe hyperparathyroidism often demands early parathyroidectomy for survival.
No clinical trial data, no response rates, and no survival statistics are reported for any drug in these abstracts. The 2021 case report does not describe any pharmacological treatment or its outcome. What is missing is any prospective trial testing a drug for FHH3, any validated patient stratification beyond genetic diagnosis, and dedicated funding for such studies.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Frontiers of hormone research · 2018 · 23 citations
Familial Hypocalciuric Hypercalcemia and Neonatal Severe Hyperparathyroidism
AbstractFamilial hypocalciuric hypercalcemia (FHH) and neonatal severe hyperparathyroidism (NSHPT) are genetically determined variants of primary hyperparathyroidism. FHH usually has a benign course, and patients do not require treatment, whereas NSHPT is a severe disorder often requiring early parathyroidectomy for young patients to survive. Recent discoveries in the genetic basis and new findings in therapeutic approaches have led to a great interest in these rare diseases.
Current Opinion in Endocrinology & Diabetes · 1997 · 2 citations
Familial hypocalciuric hypercalcemia
AbstractFamilial hypocalciuric hypercalcemia (FHH) is usually caused by inactivating mutations in the extracellular calcium-sensing receptor. Most such mutations are missense. Expression studies of mutant receptors are now more precisely characterizing the nature of the signaling defect caused by these mutations. Reports of additional patients with FHH and neonatal severe hyperparathyroidism and their associated caiciumsensing receptor defects are expanding our understanding of the clinical spectrum of these diseases as well as adding to structure function information about the calcium-sensing receptor. At least two other FHH genes exist. They have yet to be identified.
Università degli Studi di Pavia · 2013 · 0 citations · open access
A case of persistent hypercalcaemia
AbstractFamilial hypocalciuric hypercalcaemia (FHH) is a genetically determined, rare, benign and asymptomatic condition, inherited as autosomal dominant trait. First described in 1966, FHH is caused by an inactivating mutation in the extracellular calcium levels -sensing receptor gene, CASR, (cloned in 1993). We report the case of a young diabetic man hospitalized for necrotizing fasciitis during whose long-lasting recovery we observed persistent hypercalcemia.
Journal of the Endocrine Society · 2021 · 0 citations · open access
Clinical Presentation and Management Approach in a Case of Familial Hypocalciuric Hypercalcemia Type 3 Due to APS21 Gene Mutation
AbstractAbstract Familial hypocalciuric hypercalcemia (FHH) is a genetic disorder caused by dysfunctional calcium homeostasis. Thus far, three types of FHH are known to be caused by mutations inCASR (FHH1), GNA11 (FHH2), and AP2S1 (FHH3). The patient in this case report is a 36-year old male that initially presented for a second opinion after being diagnosed with Primary Hyperparathyroidism(PHPT) with subsequent parathyroidectomy done at another institute, and developed recurrent symptomatic hypercalcemia. Prior to considering this patient for further surgical options, he underwent genetic testing, which revealed he had c.43C>T (p.Arg15Cys) mutation in the AP2S1 gene diagnostic of Familial Hypocalciuric Hypercalcemia Type 3 (FHH3). The patient’s father and sister also have hypercalcemia, and have been offered genetic testing. There have been cases reported of patients with FHH3 that have symptomatic hypercalcemia and that have associated cognitive issues. Many patients with FHH can be misdiagnosed and may undergo unnecessary parathyroidectomy. This case report further elucidates the need to raise awareness of FHH.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
